WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene today announced its ASCO poster detailing the results of a study characterizing the differences between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC), including distinct genomic alterations, gene expression, transcriptomic features, TMEs, and biomarkers, received a GRASP Advocate Choice Award.
GRASP (Guiding Researchers and Advocates to Scientific Partnerships) is a nonprofit, patient-led organization committed to accelerating and improving cancer treatments by connecting patients, clinicians, and researchers. GRASP was started in 2019 by two breast cancer survivors and advocates who identified a need for breaking down silos and fostering connections within the cancer community. GRASP, held in conjunction with the 2023 American Society of Clinical Oncology annual meeting, took place on June 14-15, 2023. The poster was presented by Jason Mouabbi, MD, assistant professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, on behalf of researchers at BostonGene and MD Anderson.
The study, Differential genomic and transcriptomic analysis of invasive lobular and ductal carcinomas, which analyzed samples from patients treated at MD Anderson, describes the use of BostonGene’s integrated genomic and transcriptomic analysis platform to provide an in-depth understanding of the molecular differences between two breast cancer subtypes, ILC and IDC. The results revealed mechanistic insights for both subtypes that can be used to tailor ILC-specific interventional clinical trials, which can help discover more effective personalized treatment options for patients with this aggressive subtype.
“We are honored to receive this award based on the collaborative research effort, which recognizes our continued commitment to cancer research and developing innovative solutions to advance patient care,” said Krystle Nomie, PhD, VP, Research Partnerships at BostonGene.
About BostonGene Corporation
BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and reduce overall cost of cancer care. BostonGene’s tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.